SC-19220 is primarily used in research settings as a selective antagonist for the EP1 receptor, which is one of the four subtypes of prostaglandin E2 (PGE2) receptors. Its application is significant in studying the role of PGE2 in various physiological and pathological processes. Researchers utilize SC-19220 to investigate the involvement of EP1 receptors in pain signaling, inflammation, and certain types of cancer. By blocking the EP1 receptor, it helps to elucidate the mechanisms underlying these conditions and contributes to the development of potential therapeutic strategies targeting PGE2 pathways. Additionally, SC-19220 is employed in experimental models to understand its effects on smooth muscle contraction, particularly in the context of cardiovascular and gastrointestinal systems. Its use in these studies provides valuable insights into the complex interactions of prostaglandins in the body.